CIDRAP newsletters options
Doctors say antibiotic resistance and improper prescribing are problems, but not in their practices.
However, a top WHO official warned that calm waters doesn't mean the storm is over, and most of the world is still susceptible to the easily spreading virus.
The southern half of the country continues to report the highest death tolls, which nationally may be higher than thought, based on new excess death estimates.
A case report today in the Centers for Disease Control and Prevention's (CDC's) Morbidity and Mortality Weekly Report describes three cases of multidrug-resistant tuberculosis (MDR-TB) among workers at an Ohio food-processing facility.
In another development, China reported an infection in a patient who was sick 6 months ago, stoking worries about waning immunity.
The summer decline in social distancing has triggered a spike in bar and restaurant outbreaks, as colleges brace for spread on campuses when students return.
New data from a phase 1/2 clinical trial of a vaccine candidate being developed by Pfizer and German biopharmaceutical company BioNTech show the vaccine produced a robust immune response and was tolerable in healthy adults. The results appeared today in Nature.
Tests in the Democratic Republic of Congo (DRC) have confirmed five more Ebola cases in the Equateur province outbreak, lifting the total to 84, the World Health Organization (WHO) African regional office said on Twitter today.
Also, three more people died from their infections, raising the fatality count to 36.
Russia's vaccine hasn't been through phase 3 trials, raising worries that the country is skipping key safety steps.
Health risks to student-athletes led to the decision, and in other developments, nursing homes warned of rising infections and took steps to tighten restrictions.
CARB-X announced today that it is awarding $2.91 million to German drug developer Evotec SE to develop a new class of antibiotics to treat infections caused by multidrug-resistant bacteria.
The National Institute of Allergy and Infectious Diseases (NIAID) yesterday announced that it is enrolling participants for two phase 3 trials of two different monoclonal antibody treatments for COVID-19.
As cases surge in intense transmission countries, illness levels are rising in countries that curbed the spread, including many in Europe.
In a prospective study, the test accurately predicted patients who could be cured with the oral antibiotic.
Meanwhile, experts warn that a window of opportunity to control the virus is short, ahead of a likely new COVID-19 surge in the fall.
Two more Ebola cases were confirmed in the Democratic Republic of Congo (DRC) outbreak in Equateur province, bringing the total to 79, the World Health Organization (WHO) African regional office said today in a Twitter update.
No new deaths were reported, keeping the fatality count at 33.
Cases in Africa passed the 1 million mark, as more countries in Europe reported notable spikes in cases.
In other developments, the CDC and the State Department lifted international travel bans and lawmakers remained at odds over the latest COVID-19 relief package.
Patients with confirmed asymptomatic COVID-19 infections shed virus at similar levels to those who are experiencing symptoms, underscoring the importance of public health actions to control the spread of the virus, researchers from South Korea reported yesterday in JAMA Internal Medicine.
A web-based survey of physicians in 23 countries indicates widespread broad-spectrum antibiotic use in COVID-19 patients, an international team of researchers reported today in the Journal of Antimicrobial Chemotherapy.
